China Historical Financial Ratios
| CPHI Stock | USD 0.20 0.01 4.76% |
China Pharma is presently reporting on over 121 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0019, PTB Ratio of 0.29 or Days Sales Outstanding of 32.76 will help investors to properly organize and evaluate China Pharma Holdings financial condition quickly.
China |
About China Financial Ratios Analysis
China Pharma HoldingsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate China Pharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on China financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across China Pharma history.
China Pharma Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing China Pharma Holdings stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on China Pharma sales, a figure that is much harder to manipulate than other China Pharma Holdings multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is China Pharma Holdings dividend as a percentage of China Pharma stock price. China Pharma Holdings dividend yield is a measure of China Pharma stock productivity, which can be interpreted as interest rate earned on an China Pharma investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Most ratios from China Pharma's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into China Pharma Holdings current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in China Pharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. As of now, China Pharma's Payables Turnover is increasing as compared to previous years. The China Pharma's current Research And Ddevelopement To Revenue is estimated to increase to 0.04, while Price To Sales Ratio is projected to decrease to 0.28.
| 2023 | 2024 (projected) | Dividend Yield | 0.002105 | 0.00187 | Price To Sales Ratio | 0.29 | 0.28 |
China Pharma fundamentals Correlations
Click cells to compare fundamentals
China Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
China Pharma fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 4.72 | 8.95 | 11.54 | 3.11 | 0.29 | 0.28 | |
| Ptb Ratio | 5.59 | 12.15 | 18.5 | 5.88 | 0.27 | 0.29 | |
| Days Sales Outstanding | 22.79 | 19.59 | 31.62 | 20.92 | 34.48 | 32.76 | |
| Book Value Per Share | 2.12 | 1.83 | 1.3 | 0.82 | 2.2 | 2.09 | |
| Free Cash Flow Yield | 0.009154 | (0.009354) | (0.00618) | (0.0322) | (0.35) | (0.33) | |
| Operating Cash Flow Per Share | 0.14 | (0.009687) | (0.0542) | (0.0779) | (0.21) | (0.2) | |
| Capex To Depreciation | 0.0464 | 0.32 | 0.14 | 0.15 | 0.004182 | 0.003973 | |
| Pb Ratio | 5.59 | 12.15 | 18.5 | 5.88 | 0.27 | 0.29 | |
| Ev To Sales | 5.04 | 9.54 | 12.34 | 3.94 | 0.75 | 0.71 | |
| Free Cash Flow Per Share | 0.16 | 0.28 | 0.11 | (0.21) | (0.15) | (0.22) | |
| Roic | (0.22) | (0.18) | (0.2) | (0.7) | (0.23) | (0.24) | |
| Inventory Turnover | 2.05 | 2.63 | 2.41 | 2.78 | 2.92 | 1.48 | |
| Net Income Per Share | (4.82) | (0.72) | (0.85) | (1.94) | (0.91) | (0.86) | |
| Days Of Inventory On Hand | 138.74 | 151.72 | 131.18 | 125.14 | 186.82 | 248.36 | |
| Payables Turnover | 6.91 | 7.22 | 10.03 | 12.89 | 7.55 | 14.36 | |
| Research And Ddevelopement To Revenue | 0.021 | 0.0348 | 0.0331 | 0.0229 | 0.0342 | 0.0388 | |
| Cash Per Share | 0.26 | 0.23 | 1.07 | 0.39 | 0.44 | 0.51 | |
| Pocfratio | 84.82 | (2.3K) | (445.53) | (61.61) | (2.93) | (3.07) | |
| Interest Coverage | (10.54) | (8.35) | (5.75) | (8.17) | (8.25) | (7.84) | |
| Capex To Operating Cash Flow | 0.22 | (20.52) | (1.75) | (0.98) | (0.0165) | (0.0173) | |
| Pfcf Ratio | 109.25 | (106.9) | (161.81) | (31.09) | (2.88) | (3.02) | |
| Days Payables Outstanding | 52.82 | 50.56 | 36.4 | 28.32 | 48.37 | 68.97 | |
| Income Quality | (0.0294) | 0.0147 | 0.0735 | 0.1 | 0.23 | 0.24 | |
| Roe | (0.36) | (2.28) | (0.39) | (0.65) | (2.38) | (0.41) | |
| Ev To Operating Cash Flow | 90.53 | (2.5K) | (476.06) | (78.04) | (7.51) | (7.89) | |
| Pe Ratio | (2.45) | (30.76) | (28.24) | (2.47) | (0.66) | (0.7) | |
| Return On Tangible Assets | (0.24) | (0.97) | (0.15) | (0.18) | (0.66) | (0.25) | |
| Ev To Free Cash Flow | 116.6 | (114.02) | (172.9) | (39.38) | (7.39) | (7.76) | |
| Earnings Yield | (0.19) | (0.41) | (0.0325) | (0.0354) | (1.5) | (1.43) | |
| Intangibles To Total Assets | 0.0274 | 0.0291 | 0.026 | 0.12 | 0.22 | 0.23 | |
| Net Debt To E B I T D A | (0.2) | 60.55 | 33.12 | (8.03) | 380.53 | 399.56 | |
| Current Ratio | 0.87 | 0.56 | 0.47 | 0.86 | 0.88 | 0.84 | |
| Tangible Book Value Per Share | 1.98 | 1.69 | 1.18 | 0.4 | 1.12 | 1.07 | |
| Receivables Turnover | 16.02 | 18.63 | 11.54 | 17.45 | 10.58 | 11.11 | |
| Graham Number | 15.17 | 5.47 | 5.01 | 5.98 | 6.72 | 6.38 |
Currently Active Assets on Macroaxis
When determining whether China Pharma Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Pharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Pharma Holdings Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in China Pharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.63 | Quarterly Revenue Growth (0.16) | Return On Assets (0.18) | Return On Equity (0.75) |
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.